Tag Archives: generic drugs
A Billion Here, A Billion There: Selectively Disclosing Actual Generic Drug Prices Would Save Real Money
Selectively disclosing de-identified information on generic ingredient costs would enable health plans to negotiate reduced reimbursements to retail pharmacies for generic drugs.
September 12, 2017
On May 11, the Senate Committee on Health, Education, Labor and Pensions marked up the proposed FDA user fee reauthorization bill and voted 21-2 to advance it to the full Senate. The bill would reauthorize the fee system for FDA approval of drugs, medical devices, generic drugs, and biosimilars.
May 15, 2017
In a presidential administration whose confirmation hearings have sparked more than a few contentious moments, FDA Commissioner-designate Scott Gottlieb’s confirmation hearing was remarkable for how unremarkable it was. But to say the hearing was uneventful is not to say that it was uninteresting.
April 7, 2017
The generics market has been in turmoil---shortages, price spikes, quality issues, compounding abuses---since 2008. What can be done to create a healthy marketplace?
March 21, 2016
Meaningful intellectual property ownership for older medications expired decades ago, and they are now subject to massive price increases or severe shortages. This need not be the case, and there are remedies to address these problems.
February 23, 2016
With the upcoming Presidential election, health care is once again keeping us up at night. How much of the current debate is hyperbolic rhetoric? What policy changes are realistic in an election year? What market trends in the private sector will drive the most change?
December 30, 2015
The FDA's approval this year of the first biosimilar has prompted a flurry of regulatory activity. Key concerns raised by recent FDA guidance remain, as well as other widely anticipated but yet-to-be released regulatory activity, such as the pivotal interchangeability standard.
December 14, 2015
Several studies have examined the underlying sources for the recent slowdown in health care spending. However, they do not account for the full decline in spending, or raise questions about the pattern and timing of the slowdown.
November 18, 2015
US law governing prescription pharmaceutical markets gives every new drug a long-term monopoly that prohibits competition. High prices and slow innovation cycles are the inevitable result and will remain so unless Congress makes fundamental changes in existing law.
October 29, 2015
Counting and identifying manufacturers able to supply the U.S. with generic drugs or their base ingredients is critical for promoting public health goals, yet the number and identity of these manufacturers is shrouded from public oversight. We recommend three measures that the U.S. Congress...
October 16, 2015